1. Abed, Y., Goyette, N., and Boivin, G. 2004. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir. Ther. 9, 577–581.
2. Bischofberger, N., Kim, C., Lew, W., Liu, H., and Williams, M. 1998. Carboxylic compounds. U.S. patent 5,763,483.
3. FDA 2017. The FDA approves first generic version of widely used influenza drug, Tamiflu. last updated August 04, 2016, available at https://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ ucm514854.htm.
4. Green, M.D., Nettey, H., and Wirtz, R.A. 2008. Determination of oseltamivir quality by colorimetric and liquid chromatographic methods. Emerg. Infect. Dis. 14, 552–556.
5. Grigoriev, A., Borisova, I., Yaroshenko, I., and Sidorova, A. 2016. In vitro and in vivo stability of oseltamivir within a bioequivalence trial. Anal. Bioanal. Chem. 408, 3891–3897.